Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 60, Issue 5, Pages 3187-3192Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02638-15
Keywords
-
Categories
Funding
- HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [K08AI114883, R21AI111037]
Ask authors/readers for more resources
Aminoglycoside treatment of carbapenem-resistant (CR) Klebsiella pneumoniae bacteremia was associated with a 70% rate (23/33) of 30-day survival. Successful treatment was associated with sources of bacteremia amenable to reliable aminoglycoside pharmacokinetics (P = 0.037), acute physiology and chronic health evaluation II (APACHE II) scores of <20 (P = 0.16), and nonfatal underlying diseases (P = 0.015). Success rates were 78% and 100% if >= 2 and all 3 factors were present, respectively. Clinicians may consider the use of aminoglycosides against CR K. pneumoniae bacteremia if strains are susceptible and the sources of infection are amenable to reliable pharmacokinetics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available